Projects / Programmes source: ARIS

Pathology and Molecular Genetics

Research activity

Code Science Field Subfield
3.04.00  Medical sciences  Oncology   
3.01.00  Medical sciences  Microbiology and immunology   

Code Science Field
B000  Biomedical sciences   

Code Science Field
3.02  Medical and Health Sciences  Clinical medicine 
3.01  Medical and Health Sciences  Basic medicine 
Evaluation (rules)
source: COBISS
Researchers (59)
no. Code Name and surname Research area Role Period No. of publicationsNo. of publications
1.  33147  PhD Luka Bolha  Biochemistry and molecular biology  Researcher  2017 - 2019  27 
2.  25441  PhD Emanuela Boštjančič  Microbiology and immunology  Researcher  2014 - 2019  121 
3.  26229  Tina Bukovec    Technical associate  2019 
4.  05367  PhD Anton Cerar  Oncology  Researcher  2014 - 2016  194 
5.  53705  Alenka Dečman Cerar    Technical associate  2019 
6.  17953  Magdalena Dimnik    Technical associate  2015 - 2017 
7.  06207  Zvezdana Dolenc-Stražar  Microbiology and immunology  Technical associate  2014 - 2019  77 
8.  39127  PhD Ana Dolinar  Chemistry  Junior researcher  2016 - 2019  20 
9.  02273  PhD Dušan Ferluga  Microbiology and immunology  Retired researcher  2014 - 2019  531 
10.  39720  Zdenka Flis    Technical associate  2016 - 2019 
11.  53997  Maja Frelih    Technical associate  2019  35 
12.  02127  PhD Nina Gale  Oncology  Retired researcher  2014 - 2019  406 
13.  53736  Katarina Gašperlin    Technical associate  2019 
14.  09275  PhD Damjan Glavač  Chemistry  Researcher  2014 - 2019  565 
15.  39128  PhD Gašper Grubelnik  Microbiology and immunology  Junior researcher  2016 - 2019  31 
16.  26059  Katarina Hafner    Technical associate  2015 - 2017 
17.  27704  PhD Nina Hauptman  Chemistry  Researcher  2014 - 2019  105 
18.  33098  PhD Mateja Jelen  Microbiology and immunology  Technical associate  2015 - 2016  47 
19.  26231  PhD Borut Jerman  Biochemistry and molecular biology  Researcher  2014 - 2015  24 
20.  20201  PhD Maja Jerše  Oncology  Researcher  2014 - 2019  50 
21.  19130  PhD Jera Jeruc  Microbiology and immunology  Researcher  2014 - 2019  166 
22.  34275  PhD Daša Jevšinek Skok  Veterinarian medicine  Researcher  2016 - 2018  86 
23.  11204  PhD Vesna Jurčić  Microbiology and immunology  Researcher  2014 - 2019  149 
24.  22462  PhD Nika Kojc  Oncology  Researcher  2014 - 2019  187 
25.  52857  Danijela Kolenc    Technical associate  2019  52 
26.  38018  Evelin Krajnc  Pharmacy  Technical associate  2015 
27.  39721  Vlasta Krfogec    Technical associate  2016 - 2017 
28.  07133  PhD David Križaj  Oncology  Researcher  2014 - 2019  84 
29.  18455  Žiga Kušar  Neurobiology  Technical associate  2017 - 2019 
30.  53704  Anja Ličen    Technical associate  2019 
31.  15472  PhD Boštjan Luzar  Oncology  Researcher  2014 - 2019  457 
32.  35428  PhD Alenka Matjašič  Oncology  Technical associate  2014 - 2019  36 
33.  27668  MSc Anja Milenković Kramer  Economics  Technical associate  2017  12 
34.  53703  Milena Milić    Technical associate  2019 
35.  21348  PhD Urša Mohar  Pharmacy  Technical associate  2017 
36.  50900  Miša Omerzel    Technical associate  2017 
37.  53706  Mateja Osvald    Technical associate  2019 
38.  53702  Metod Perme    Technical associate  2019 
39.  23082  PhD Martina Perše  Oncology  Researcher  2014 - 2019  206 
40.  26053  PhD Živa Pipan Tkalec  Biology  Technical associate  2017  42 
41.  26058  PhD Jože Pižem  Oncology  Researcher  2014 - 2019  172 
42.  36130  Jerica Pleško    Technical associate  2014 - 2019  33 
43.  07090  PhD Mara Popović  Neurobiology  Researcher  2018 - 2019  306 
44.  20345  PhD Uroš Rajčević  Oncology  Researcher  2014  118 
45.  01502  PhD Metka Ravnik-Glavač  Biochemistry and molecular biology  Researcher  2014 - 2019  268 
46.  19141  PhD Irena Srebotnik Kirbiš  Oncology  Technical associate  2014 - 2019  92 
47.  14669  PhD Margareta Strojan Fležar  Oncology  Researcher  2014 - 2019  264 
48.  38406  Sanja Tepavac    Technical associate  2015 - 2016 
49.  51957  PhD Ana Unkovič  Medical sciences  Junior researcher  2018 - 2019 
50.  51961  PhD Kristian Urh  Medical sciences  Junior researcher  2018 - 2019  22 
51.  18362  Daniel Velkavrh    Technical associate  2015 - 2017 
52.  07182  PhD Alenka Vizjak  Microbiology and immunology  Retired researcher  2014 - 2019  377 
53.  12956  PhD Metka Volavšek  Oncology  Researcher  2014 - 2019  238 
54.  34352  PhD Katarina Vrabec  Oncology  Junior researcher  2014 - 2016  18 
55.  50899  Karmen Wechtersbach  Oncology  Technical associate  2017  14 
56.  12955  PhD Nina Zidar  Microbiology and immunology  Head  2014 - 2019  388 
57.  28143  PhD Andrej Zupan  Oncology  Researcher  2014 - 2019  54 
58.  53996  Milanka Živanović  Oncology  Technical associate  2019 
59.  51028  PhD Margareta Žlajpah  Oncology  Technical associate  2017 - 2018  22 
Organisations (1)
no. Code Research organisation City Registration number No. of publicationsNo. of publications
1.  0381  University of Ljubljana, Faculty of Medicine  Ljubljana  1627066  48,524 
The research on squamous intraepithelial lesions (SIL) and invasive squamous cell carcinoma of the head and neck (SCCHN) will focus on the preparation of a uniform classification of SIL with the aid of the results of an international study. In the part of the research of human papilloma virus (HPV) and the development of SSC, we will examine the role of low-risk HPV in this process and the role of high risk HPV in the occurrence of the variant of SCC, verrucous carcinoma (VC). Possible changes in the signaling pathway PI3K/Akt/mTOR in the occurrence of HPV-pos. SCC and HPV-neg. SCC will contribute to new understandings of the carcinogenesis of SCCHN. On tissue samples of the uterine cervix (UC) we will analyse the predictive significance of p16 for progression to cervical intraepithelial neoplasia (CIN) and of podoplanin for discovering early stromal invasive SCC. We will analyse the predictive significance of DNA ploidy for prostate cancer in patients with low risk of disease progression.   Mutations and epigenetic events influence the development of different diseases, which we will determine in our molecular-genetic research using some of the new technologies as next generation sequencing, high-resolution comparative genome hybridization, microarrays, methylation-specific HRM, quantitative RT-PCR. We will analyse diseases including Leber syndrome, gynecomastia with pseudoangiomatous stromal hyperplasia and stromal giant cells in association with neurofibromatosis type 1, amyotrophic lateral sclerosis, malignant glioma, melanocytic lesions, and colorectal carcinoma. Multilevel approach enabling to analyse changes in DNA, mRNA, ncRNA and epigenetic status will be used. With this approach it will be possible to discover new disease-related changes, which were missed in the past due to the limitations of used technologies. Some of these new findings might be promising biomarkers as well as diagnostic and therapeutic targets.   Our research of immune and non-immune diseases of the kidneys and blood vessels will be continued in close collaboration among pathology, laboratory and clinical medicine enabling the direct transfer of scientific results into diagnostics and patient treatment. Among systemic and diseases restricted to the kidneys, which have in common impairment of humoral immune response, particular stress will be given to identifying factors that affect the variable course of frequent IgA nephropathy (IgAN), to studying monoclonal immunoglobulin deposition diseases and to assessing the coexisting immunopathogenesis in patients with anti-GBM antibodies. Electron microscopic results in correlation with the histopathology and clinical course will be to the fore, especially in the continuation of research related to kidney injury in phospholipidosis. We plan to supplement our original findings on hantavirus nephropathy in the acute phase of the disease with results on the histopathology of the still entirely unsearched chronic phase of the disease.
Significance for science
The international study with trial introduction of a uniform classification of SIL HN, with the cooperation of experts from 4 countries, will have particular importance. With the possible adoption of diagnostic criteria our proposal could be an important basis for a uniform classification of SIL in future editions of the book WHO Head and Neck Tumours. The results of the research connected with HPV6/11 in the carcinogenesis of SCC, with HPV infection in the occurrence of VC in various organs and the comparison of changes in the signalling pathway PI3K/Akt/mTOR in the occurrence of SCC with HPV-pos. SCC and HPV-neg. SCC will significantly contribute to knowledge of carcinogenesis in connection with HPV infection. Understanding the role of HPV in the development of various tumours will also assist in the selection of populations for vaccination. Expression of p16 is important for evaluating various grades of CIN, which can consequentially affect the share of high grade CIN in screening programmes of early discovery of cervical cancer. Changes in the expression of podoplanin in early stromal carcinoma invasion will markedly contribute to more reliable histopathological assessment of SCC DNA ploidy is an additional predictive factor in prostate cancer.   New genomic technologies have significantly accelerated the discovery of coding and non-coding changes and the complexity of the processes that lead to the disease condition (e.g. the discovery of the Notch 1 gene in connection with squamous cell carcinoma of the head and neck). We expect altered expression of lncRNA in relation to different glioma grades and differentiation. We expect altered miRNA expression in relation to received oncotherapy and survival of patients with malignant glioma. Similarly we expect to detect in all examined disease states due to our multilevel approach and the use of combination of different methods changes in DNA, RNA, and epigenetics, which will contribute to the understanding of relations at the level of genome, transcription and regulation, of the correlations between the diseases and their molecular basis, and of the improvement of diagnosis, prognosis and treatment   The scientific achievements of our research can be expected to contribute to clarifying the occurrence and development of specific immune and non-immune diseases of the kidneys and blood vessels, improving disease recognition, monitoring the natural disease course and the effects of treatment. Very precise research and identifying undesirable, still very inadequately identified side effects of chloroquine treatment in kidney tissues of patients for whom, on the basis of ever more numerous publications in the literature, it has a beneficial effect in the treatment of rheumatic diseases, is particularly important.
Significance for the country
Through our research of SIL HN, we have become one of the leading centres in this field both at home and abroad. We expect that our study will contribute to the uniformity of SIL assessment and the possibility of comparison of individual forms of treatment. The research on the link of HPV infection and the development of SCCHN will provide a clearer picture of this health problem in Slovenia since we do not have detailed data on how large a part of SCCHN is connected with high risk HPV infection; treatment of HPV-pos. and HPV-neg. SCC differ significantly. Histopathological diagnosis of CIN and UC SCC influences the incidence of precancerous changes and cancer of the UC. The study on p16 and podoplanin will contribute to national recommendations for assessing these changes. Determining DNA ploidy will contribute to individual planning of the treatment of patients with prostate cancer with low or medium risk of disease recurrence.   The proposed molecular genetic research will make possible to introduce new methods and diagnostic approaches in Slovenia. Patients with Leber syndrome and amyotrophic lateral sclerosis have not yet been explored in the Slovenian population. The genetic factors influencing the treatment of malignant gliomas also have not been identified. We expect to discover new genomic changes, also rare duplication and deletions, which might be specific for a certain disease. In case of ncRNA we expect new lncRNA and miRNA as potential biomarkers, which may contribute to earlier and more reliable diagnosis, prognosis of disease and more targeted treatment. In the future, all these may contribute to prevention and early diagnosis of disease, improving patient’ survival and reducing the treatment costs.   Research of the pathology of immune and non-immune diseases of the kidneys and blood vessels in the context of interdisciplinary cooperation contributes to the advancement and maintenance of a high level of diagnostics and treatment of patients in Slovenia. It speeds up the introduction of new methods in practice and enables development in accordance with internationally established standards of excellence. Patients with severe, clinically otherwise hard to recognise kidney diseases have direct benefit, since objective exact biopsy diagnosis is often the main support to clinicians in the choice of the most appropriate treatment. Because of adverse side effects, contemporary forms of treatment in nephrology can be risky; some are expensive but effective if the start of treatment is timely and based on clearly defined reliable biopsy diagnosis.   The scientific achievements of our research contribute to the quality of education at undergraduate and postgraduate levels. In addition, the publications of our researchers in prominent international journals and invited lectures at international congresses contribute to Slovenia's reputation in the world.
Most important scientific results Annual report 2014, 2015, final report
Most important socioeconomically and culturally relevant results Annual report 2014, 2015, final report
Views history